S
Surgical Science
Develops virtual reality simulators for evidence-based laparoscopic and endoscopic training
About Surgical Science
Surgical Science Sweden AB is a publicly traded Swedish company specializing in virtual reality simulators for evidence-based medical training. Founded in 1997 and headquartered in Gothenburg, Sweden, the company has established a significant global presence, with its shares traded on the Nasdaq First North Growth Market in Stockholm. The firm's strategic direction has been significantly shaped by key leadership, including Roland Bengtsson, who has served on the board since 2005 and was chairman from 2017 to 2025, and Gisli Hennermark, who held the CEO position from 2015 to 2024. Hennermark, who has a background in management consulting and entrepreneurship, transitioned to a board role in 2025.
The company's business is structured into two primary segments: Educational Products and Industry/OEM. The Educational Products division provides simulators directly to academic institutions and hospitals for training medical professionals, often utilizing a network of distributors. The Industry/OEM segment collaborates with medical technology companies, embedding its simulation software into their hardware, particularly in the rapidly growing robotic surgery market. This B2B model generates revenue through development fees for software customization and, crucially, recurring license revenues. In a significant strategic shift, Surgical Science is moving towards a subscription-based model, exemplified by its 2025 agreement with its largest customer, Intuitive, to integrate its software into all da Vinci 5 robotic systems.
Surgical Science has pursued an aggressive growth strategy marked by key acquisitions that have consolidated its market position. The acquisitions of SenseGraphics in 2019, followed by Mimic Technologies and Simbionix in 2021, and Intelligent Ultrasound in 2025, have absorbed major competitors and significantly expanded the company's technology portfolio and market reach. These moves have created a near-monopoly in the medical simulation space for robotic surgery. The company's product lineup is extensive, offering simulators for a wide range of procedures including laparoscopy (LapSim), endoscopy (GI Mentor), bronchoscopy (BRONCH Mentor), endovascular procedures (Angio Mentor), and robotic surgery (RobotiX Mentor, FlexVR). These platforms provide a safe, repeatable, and realistic environment for surgeons to develop and refine their skills without risk to patients.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1999
- Headquarters
- Göteborgs Stad, Sweden
- Listing
- IPO 2017
- Sector
- Health
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- UGUniversity of Gothenburg
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Surgical Science on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Surgical Science on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.